Up­dat­ed: Roche buys obe­si­ty and di­a­betes biotech Car­mot Ther­a­peu­tics in $2.7B merg­er deal

Roche is jump­ing back in­to the GLP-1 space with a de­fin­i­tive merg­er agree­ment to ac­quire Car­mot Ther­a­peu­tics for $2.7 bil­lion up­front. The deal gives Roche …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER